DMTr-LNA-G(iBu)-3′-CED-phosphoramidite (CAS: 206055-77-8) is a high-performance reagent for synthesizing LNA-modified oligonucleotides. The LNA modification increases binding affinity and stability, making it perfect for therapeutic, diagnostic, and research purposes. The iBu group protects the guanine base during synthesis, while the DMTr group allows for easy monitoring.
Key Features:
- LNA Modification: Boosts stability and binding affinity, ensuring strong and durable oligonucleotides.
- iBu Protection: Safeguards the guanine base, ensuring a smooth and efficient synthesis process.
- DMTr Group: Enables easy monitoring and purification during synthesis, simplifying the workflow.
Applications:
- Oligonucleotide Synthesis: Ideal for creating LNA-modified oligonucleotides for research and medical applications.
- Therapeutics: Perfect for developing stable antisense oligonucleotides and RNA-based therapies.
- Diagnostic Probes: Used in the creation of high-affinity probes for molecular diagnostics.
Benefits:
- High Stability: The LNA modification significantly enhances resistance to degradation, making oligonucleotides more durable.
- Improved Binding: Increases hybridization affinity, resulting in stronger and more accurate binding to targets.
- Efficient Synthesis: The DMTr group simplifies tracking and purification, ensuring high-quality oligonucleotides.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
